This study is being conducted to evaluate the safety, efficacy (clinical and
microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it
would be a suitable antibiotic for the treatment for febrile lower cUTI and
pyelonephritis(complicated and uncomplicated). GSK2251052 will be compared to
imipenem-cilastatin, which is an antibiotic commonly used to treat serious cUTI infections.
GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for
cUTI.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Cilastatin Cilastatin, Imipenem Drug Combination Imipenem